The Functional Phenotype of the Primitive Plasma Cell in Patients with Multiple Myeloma Correlates with the Clinical State

References

• Hata H., Xiao H., Petrucci M. T., Woodliff J., Chang R., Epstein J. Interleukin 6 gene expression in multiple myeloma: a characteristic of immature turnour cells. Blood 1993; 81: 3357–3364
   PubMed Web of Science ®Google Scholar
• Harada H., Kawano M. M., Huang N., Harada Y., Iwato K., Tanabe O., Tanaka H., Sakai A., Asaoku H., Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 263–2663
   Google Scholar
• Kawano M. M., Huang N., Harada H., Sakai A., Tanaka H., Iwato K., Kuramao A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564–570
   PubMed Web of Science ®Google Scholar
• Jensen G. S., Mant M. J., Belch A. J., Berensen J. R., Ruether B. A., Pilarski L. M. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B-cells. Blood 1991; 78: 711–719
   PubMed Web of Science ®Google Scholar
• Omede P., Boccadoro M., Fusaro A., Gallone G., Pileri A. Multiple myeloma: “early” plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Br. J. Haematol. 1993; 85: 504–513
   PubMed Web of Science ®Google Scholar
• Joshua D. E., Petersen A., Brown R., Pope B., Snowden L., Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelo-matosis. Br. J. Haematol. 1996; 94: 76–81
   PubMed Web of Science ®Google Scholar
• Harada Y., Kawano M. M., Huang N., Mahoud M. S., Lisukov I. A., Mihara K., Tsujimoto T., Kuramoto A. Identification of early plasma cells in peripheral blood and their clinical significance. Br. J. Haematol. 1996; 92: 184–191
   PubMed Web of Science ®Google Scholar
• Bakkus M. H., Heirman C., van Reit I., Van Camp B., Theilmans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326–2335
   PubMed Web of Science ®Google Scholar
• Ralph Q. M., Brisco M. J., Joshua D. E., Brown R. D., Gibson J., Morley A. A. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood 1993; 82: 202–206
   PubMed Web of Science ®Google Scholar
• Warburton P., Joshua D. E., Gibson J., Brown R. D. CD10 (CALLA) positive lymphocytes in myeloma: evidence that they are a malignant precursor population and are of germinal centre origin. Leuk. Lymph. 1989; 1: 11–20
   PubMedGoogle Scholar
• Cao J., Vescio R. A., Rettig M. B., Hong C. H., Kim A., Lee J. C., Lichtenatein A. K., Berenson J. R. A CD 10 positive subset of malignant cells is identified in multiple myeloma using patient specific immunoglobulin gene primers. Leukemia 1995; 9: 1948–1953
   PubMed Web of Science ®Google Scholar
• Epstein J., Xiao H. Q., He X. Y. Markers of multiple hematopoietic-cell lineages in multiple myeloma. N. Engl. J. Med. 1990; 322: 664–668
   PubMed Web of Science ®Google Scholar
• Sailer M., Vykoupil K.-F., Peest D., Coldewey R., Deicher H., Georgii A. Prognostic significance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 163 untreated patients. Eu. J. Haematol. 1995; 54: 137–146
   PubMed Web of Science ®Google Scholar
• Alexanian R., Dimopoulos M. The treatment of multiple myeloma. N. Engl. J. Med. 1994; 330: 484–489
   PubMed Web of Science ®Google Scholar
• Griepp P. R., Kyle R. A. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood 1983; 62: 166–177
   PubMed Web of Science ®Google Scholar
• Griepp P. R., Katzmann J. A., Kyle R. A. Value of beta-2-microglobulin and plasma cell labelling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219–223
   PubMed Web of Science ®Google Scholar
• Petersen A. J., Brown R. D., Pope B., Jamieson G. P., Paterson A. G. P., Gibson J., Wiley J. S., Joshua D. E. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation. Leuk. Lymph. 1994; 13: 491–499
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E. Chemotherapy in myeloma. Myeloma: Biology and management, J. S. Malpas, D. E. Bergsagel, R. A. Kyle. Oxford University Press, Oxford 1995; 373–306
   Google Scholar
• Kraut E. H., Crowley J. J., Grever M. R., Keppen M. D., Bonnet J. D., Hynes H. E., Salmon S. E. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invesr. New Drugs 1990; 8: 199–200
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Purine analogs in lymphoproliferative disorders. Leuk Lymph 1993; 11(Suppl 2)153–159
   PubMed Web of Science ®Google Scholar
• Jamieson G. P., Brocklebank A. M., Snook M. B., Sawyer W. H., Buolamwini J. K., Paterson A. R. P., Wiley J. Flow cytometric quantitation of equilibrative inhibitor-sensitive nucleoside transporter sites on human leukaemic cells. Cytomerry 1993; 14: 32–38
   PubMedGoogle Scholar
• Brown R. D., Pope B., Luo X.-F., Gibson J., Joshua D. E. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymph 1994; 16: 147–156
   PubMed Web of Science ®Google Scholar
• Petersen A., Pope B., Gibson J., Brown R. D., Snowdon L., Joshua D. E. Immature malignant plasma cells in G-CSF stimulated PBSC from myeloma. Autologous marrow and Blood Transplantation VII, K A Dicke, A Keating, 1994; 417–426
   Google Scholar
• Zhang X., Galliard J. P., Robbiard N. Reproducible obtaining of human myeloma cell lines as a model for tumour stem cell study in human multiple myeloma. Blood 1994; 83: 3654–3663
   PubMed Web of Science ®Google Scholar